乙型肝炎病毒和丙型肝炎病毒相关性肝细胞癌的研究进展

doi:10.19871/j.cnki.xfcrbzz.2022.01.019

摘要/Abstract

摘要： 乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）相关的原发性肝细胞癌（HCC）发生机制复杂,其可通过介导机体免疫功能紊乱诱导慢性炎症和产生炎性因子,调控多种癌症信号通路诱导HCC的发生和进展。HBV可通过病毒基因整合、病毒蛋白（主要是HBx、PreS）变异诱导宿主基因不稳定发生插入、缺失等突变诱导HCC的发生和进展。HCV基因组不能整合到宿主基因组,但是其可通过病毒蛋白以及调控特定的致癌通路产生活性氧（ROS）损伤宿主肝脏细胞DNA导致肝脏细胞某些基因突变进而诱导HCC的发生。目前关于病毒相关HCC的治疗除了经典的抗病毒治疗外,中医药疗法、HBx靶向治疗、血小板治疗以及工程T细胞治疗也显示出了极大的前景和优势。本篇综述通过回顾总结关于HBV/HCV相关HCC的发病机制和治疗的研究进展,提出HBV/HCV相关HCC有待解决的疑问及未来的研究方向。

关键词: 乙型肝炎病毒, 丙型肝炎病毒, 肝细胞癌, 发生机制, 临床治疗

Abstract: Hepatitis B virus (HBV) and hepatitis C virus (HCV) related primary hepatocellular carcinoma (HCC) is caused by complex mechanisms, which led to the host's immune dysfunction with chronic inflammation and to produce inflammatory factors that regulate multiple cancer signaling pathways. DNA fragment of HBV can insert into host genome to cause occurrence of HCC. Genome of HCV cannot be integrated into host genome, but it can induce the occurrence and progression of HCC by viral proteins and regulation of specific oncogenic pathways to induce reactive oxygen species(ROS) that damage host DNA and lead to gene mutation. Currently, in addition to the classic antiviral therapy, therapy of traditional Chinese medicine HBX targeted therapy, platelet therapy and engineered T cell therapy also show great prospects and advantages for the treatment of virus-associated HCC. In the review, we will summarize the research progress on the mechanism and treatment of HBV/HCV-associated HCC, and confer clues for future research directions.

Key words: Hepatitis B virus, Hepatitis C virus, Hepatocellular carcinoma, Mechanism, Treatment

李晓月, 李述捷, 易永祥. 乙型肝炎病毒和丙型肝炎病毒相关性肝细胞癌的研究进展[J]. 新发传染病电子杂志, 2022, 7(1): 92-99.

Li Xiaoyue, Li Shujie, Yi Yongxiang. Research progress in hepatocellular carcinoma associated with hepatitis B virus and hepatitis C virus[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(1): 92-99.

参考文献

[1] FERLAY J, SHIN HR, BRAY F, et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12):2893-2917.
[2] KULIK L, EL-SERAG HB.Epidemiology and Management of Hepatocellular Carcinoma[J]. Gastroenterology, 2019, 156(2):477-491.
[3] EL-SERAG HB.Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma[J]. Gastroenterology, 2012, 142(6):1264-1273.
[4] LIU CJ, KAO JH.Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors[J]. J Chin Med Assoc, 2007, 70(4):141-145.
[5] GIOVANNA F, TOMMASO S, IRENE Z, et al.Hepatocellular carcinoma in cirrhosis: Incidence and risk factors[J]. Gastroenterology, 2004, 127(5):S35-S50.
[6] SEEGER C, MASON WS. Molecular biology of hepatitis B virus infection[J]. Virology, 2015, 479-480:672-686.
[7] YANG G, FENG JY, LIU YX, et al.HAT1 signaling confers to assembly and epigenetic regulation of HBV cccDNA minichromosome[J]. Theranostics, 2019, 9(24):7345-7358.
[8] KOSTYUSHEV D, KOSTYUSHEVA A, BREZGIN S, et al.Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9[J]. Sci Rep, 2019, 9(1):1847.
[9] BELLONI L, POLLICINO T, DE NF, et al.Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.[J]. Proc Natl Acad Sci USA, 2009, 106(47):19975-19979.
[10] LIN CL, KAO JH.Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants.[J]. Best Pract Res Clin Gastroenterol, 2017, 31(3):249-255.
[11] 易永祥. 乙型肝炎病毒的分子流行病学研究进展[J/CD]. 新发传染病电子杂志, 2020, 5(1):1-7.
[12] YANG ZG, ZHUANG LP, LU YF, et al.Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis[J]. Oncotarget, 2016, 7(11):12525-12536.
[13] NORDER H, COUROUCÉ AM, COURSAGET P, et al.Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes[J]. Intervirology, 2004, 47(6):289-309.
[14] LIN CL, KAO JH.Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants[J]. Best Pract Res Clin Gastroenterol, 2017, 31(3):249-255.
[15] POLLICINO T, CACCIOLA I, SAFFIOTI F, et al.Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications[J]. J Hepatol, 2014, 61(2):408-417.
[16] HSIEH YH, SU IJ, WANG HC, et al.Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage[J]. Carcinogenesis, 2004, 25(10):2023-32.
[17] WANG HC, HUANG WY, LAI MD, et al.Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis[J]. Cancer Sci, 2006, 97(8):683-688.
[18] YE HCT, CHEN T, HSU CW, et al.Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B[J]. BMC Cancer, 2011, 11(1):398.
[19] CHISARI FV, KLOPCHIN K, MORIYAMA T, et al.Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice[J]. Cell, 1989, 59(6):1145-1156.
[20] SUNG WK, ZHENG HC, LI SY, et al.Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma[J]. Nat Genet, 2012, 44(7):765-769.
[21] HANAHAN D, WEINBERG RA.Hallmarks of Cancer: The Next Generation[J]. Cell, 2011, 144(5):646-674.
[22] ZHAO LH, LIU X, YAN HX, et al.Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma[J]. Nat Commun, 2016, 7:13591.
[23] LI XJ, ZHANG JB, YANG ZW, et al.The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma[J]. J Hepatol, 2014, 60(5): 975-984.
[24] FORGUES M, DIFILIPPANTONIO MJ, LINKE SP, et al.Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles[J]. Mol Cell Biol, 2003, 23(15):5282-5292.
[25] BOUCHARD MJ, NAVAS-MATIN S.Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges[J]. Cancer Letters, 2011, 305(2):123-143.
[26] YANG B, BOUCHARD MJ.The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake.[J]. J Virol, 2012, 86(1):313-327.
[27] LING LR, ZHENG DH, ZHANG ZY, et al.Effect of HBx on inflammation and mitochondrial oxidative stress in mouse hepatocytes[J]. Oncol Lett, 2020, 19(4):2861-2869.
[28] YOO YG, OH SH, PARK ES, et al.Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway[J]. J Biol Chem, 2003, 278(40):39076-39084.
[29] SANZ-CAMENO P, MARTÍN-VÍLCHEZ S, LARA-PEZZI E, et al. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein[J]. Am J Pathol, 2006, 169(4):1215-1222.
[30] LEE DK, PARK SH, YI Y, et al.The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis.[J]. Genes Dev, 2001, 15(4):455-466.
[31] HE B, PENG F, LI W, et al.Interaction of lncRNA-MALAT1 and miR-124 regulates HBx-induced cancer stem cell properties in HepG2 through PI3K/Akt signaling[J]. J Cell Biochem, 2019, 120(3):2908-2918.
[32] WANG Q, CHENG ST, CHEN J.HBx mediated Increase of SIRT1 Contributes to HBV-related Hepatocellular Carcinoma Tumorigenesis[J]. Int J Med Sci, 2020, 17(12):1783-1794.
[33] ZHENG BY, GAO WY, HUANG XY, et al.HBx promotes the proliferative ability of HL-7702 cells via the COX-2/Wnt/β-catenin pathway[J]. Mol Med Rep, 2018, 17(6):8432-8438.
[34] BELLONI L, POLLICINO T, DE NF, et al.Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.[J]. Proc Natl Acad Sci U S A, 2009, 106(47):19975-19979.
[35] GIERSCH K, ALLWEISS L, VOLZ T, et al.Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol, 2017, 66(2):460-462.
[36] EL-SERAG HB,RUDOLPH KL.Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.[J]. Gastroenterology, 2007, 132(7):2557-2576.
[37] KANG TW, YEVSA T, WOLLER N, et al.Senescence surveillance of pre-malignant hepatocytes limits liver cancer development[J]. Nature, 2011, 479(7374):547-551.
[38] NAULT JC, CALDERARO J, DI TL, et al.Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.[J]. Hepatology, 2014, 60(6):1983-1992.
[39] WANG XW, FORRESTER K, YEH H, et al.Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3[J]. Proc Natl Acad Sci U S A, 1994, 91(6):2230-2234.
[40] ZHAO J, WU GB, BU FF, et al.Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma[J]. Hepatology, 2010, 51(1):142-153.
[41] MURAKAMI Y, SAIGO K, TAKASHIMA H, et al.Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas[J]. Gut, 2005, 54(8):1162-1168.
[42] OZTURK M, ARSLAN-ERGUL A, BAGISLAR S, et al.Senescence and immortality in hepatocellular carcinoma[J]. Cancer Lett, 2009, 286(1):103-113.
[43] LIU H, SHI W, LUAN F, et al.Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase[J]. Virus Genes, 2010, 40(2):174-182.
[44] LUAN F, LIU H, GAO L, et al.Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT[J]. Gut, 2009, 58(11):1528-1537.
[45] FEDERICA T, VALERIA E, RENATO T, et al.Family history of liver cancer and hepatocellular carcinoma[J]. Hepatology, 2012, 55(5):1416-1425.
[46] BOYAULT S, RICKMAN DS, DE RA, et al.Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets[J]. Hepatology, 2007, 45(1):42-52.
[47] GUICHARD C, AMADDEO G, IMBEAUD S, et al.Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma[J]. Nat Genet, 2012, 44(6):694-698.
[48] LACHENMAYER A, TOFFANIN S, CABELLOS L, et al.Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.[J]. J Hepatol, 2012, 56(6):1343-1350.
[49] 乐晓华, 刘琢冰, 张香梅, 等. 乙型肝炎患者肝细胞癌着丝粒蛋白K基因启动子区域甲基化水平的初步分析[J/CD]. 新发传染病电子杂志, 2021, 6(2):84-87.
[50] MORADPOUR D, PENIN F.Hepatitis C virus proteins: from structure to function[J]. Curr Top Microbiol Immunol, 2013, 369:113-142.
[51] SIMMONDS P, BUKH J, COMBET C, et al.Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology, 2005, 42(4):962-973.
[52] BRUNO S, CROSIGNANI A, MAISONNEUVE P, et al.Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study[J]. Hepatology, 2007, 46(5):1350-1356.
[53] SAMREEN B, KHALIQ S, ASHFAQ UA, et al.Hepatitis C virus entry: role of host and viral factors[J]. Infect Genet Evol, 2012, 12(8):1699-1709.
[54] FAN HH, QIAO LH, KANG KD, et al.Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission[J]. J Virol, 2017, 91(13):e00280-17.
[55] HAGEN N, BAYER K, RÖSCH K, et al. The intraviral protein interaction network of hepatitis C virus[J]. Mol Cell Proteomics, 2014, 13(7):1676-1689.
[56] MCGIVERN DR, LEMON SM.Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer[J]. Oncogene, 2011, 30(17):1969-1983.
[57] MEDVEDEV R, PLOEN D, HILDT E.HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis[J]. Oxid Med Cell Longev, 2016, 2016:9012580.
[58] KUNDEN RD, KHAN JQ, GHEZELBASH S, et al.The Role of the Liver-Specific microRNA, miRNA-122 in the HCV Replication Cycle[J]. Int J Mol Sci, 2020, 21(16):5677.
[59] TSAI, WEI-CHIH, HSU, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis[J]. J Clin Invest, 2012, 122(8):2884-2897.
[60] ALEXANDER I, BIRKE B, OLGA S, et al.HCV and Oxidative Stress in the Liver[J]. Viruses, 2013, 5(2):439-469.
[61] RESHI ML,SU YC,HONG J.RNA Viruses: ROS-Mediated Cell Death[J]. Int J Cell biol, 2014, 2014:467452.
[62] HINO K, HARA Y, NISHINA S.Mitochondrial reactive oxygen species as a mystery voice in hepatitis C[J]. Hepatol Res, 2014, 44(2):123-132.
[63] IVANOV AV, SMIRNOVA OA, PETRUSHANKO IY, et al.HCV core protein uses multiple mechanisms to induce oxidative stress in human hepatoma Huh7 cells[J]. Viruses, 2015, 7(6):2745-2770.
[64] O'CONNELL MARIA A, HAYES JOHN D. The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic[J]. Biochem Soc Trans, 2015, 43(4):687-689.
[65] HARDER B, JIANG T, WU T, et al.Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention.[J]. Biochem Soc Trans, 2015, 43(4):680-686.
[66] BEYER TA, XU WH, TEUPSER D, et al.Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance.[J]. EMBO J, 2008, 27(1):212-223.
[67] SEKI E, BRENNER DA, KARIN M.A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches[J]. Gastroenterology, 2012, 143(2):307-320.
[68] TRINDER D,AYONRINDE OT,OLYNYK JK.HCV, iron, and oxidative stress: the new choreography of hepcidin.[J]. Gastroenterology, 2008, 134(1):348-351.
[69] FUJINAGA H, TSUTSUMI T, YOTSUYANAGI H, et al.Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species[J]. Oncology, 2011, 1:11-17.
[70] KEWMC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma.[J]. Pathologie Biologie, 2010, 58(4):273-277.
[71] WANG SH, YEH SH, LIN WH, et al.Estrogen receptor α represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4α.[J]. Gastroenterology, 2012, 142(4):989-998.
[72] BRUNO R, PUOTI M, SACCHI P, et al.Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients[J]. J Hepatol, 2006, 44(1):S146-S150.
[73] CHEN YY, LIN Y, HAN PY, et al.HBx combined with AFB1 triggers hepatic steatosis via COX-2-mediated necrosome formation and mitochondrial dynamics disorder[J]. J Cell Mol Med, 2019, 23(9):5920-5933.
[74] KOLLY P, KNÖPFLI M, DUFOUR JF. Effect of smoking on survival of patients with hepatocellular carcinoma[J]. Liver Int, 2017, 37(11):1682-1687.
[75] FUJITA K, IWAMA H, MIYOSHI H, et al.Diabetes mellitus and metformin in hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(27):6100-6113.
[76] FANNING GC, ZOULIM F, HOU J, et al.Therapeutic strategies for hepatitis B virus infection: towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11):827-844.
[77] 丁霞, 廖桂婵, 夏牧晔, 等. 探讨长期核苷(酸)类药物治疗慢性乙型肝炎患者停药后复发的影响因素[J/CD]. 新发传染病电子杂志, 2019, 4(1):52-57
[78] SERTI E, CHEPA-LOTREA X, KIM YJ, et al.Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function[J]. Gastroenterology, 2015, 149(1):190-200.
[79] SINGAL AK, SALAMEH H, KUO YF, et al.Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.[J]. Aliment Pharmacol Ther, 2013, 38(2):98-106.
[80] VADDEPALLY RK,KHAREL P,PANDEY R, et al.Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence[J].Cancers (Basel), 2020, 12(3):738.
[81] KALOS M,LEVINE BL,PORTER DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia[J].Sci Transl Med, 2011, 3(95):95ra73.
[82] FISICARO P,BARILI V,MONTANINI B, et al.Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B[J].Nat Med, 2017, 23(3):327-336.
[83] FEINS S,KONG W,WILLIAMS EF, et al.An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer[J].Am J Hematol, 2019, 94(S1):S3-S9.
[84] GEHRING AJ,HO ZZ,TAN AT, et al.Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma[J].Gastroenterology, 2009, 137(2):682-690.
[85] LI WP,GUO LJ,RATHI P, et al.Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Result in Th1 Polarization and Potent Antitumor Activity[J].Hum Gene Ther, 2017, 28(5):437-448.
[86] XU QG,YUAN SX,TAO QF, et al.A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma.[J].J Hepatol, 2019, 70(5):904-917.
[87] YANG SZ,LIU YF, FENG XB, et al.HBx acts as an oncogene and promotes the invasion and metastasis of hepatocellular carcinoma both in vivo and vitro[J]. Dig Liver Dis, 2021, 53(3):360-366.
[88] GIOVANNI S,ROBERTO A,PIETRO DL, et al.Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B[J]. Proceedings of the National Academy of Sciences of the United States of America,2012,109(32):E2165-E2172.
[89] 阎涛,毕新宇,方仪,等. 槐耳颗粒对原发性肝癌患者术后长期生存的影响[J]. 中华肝胆外科杂志,2012,18(2):99-102.
[90] 成远,华海清. 榄香烯治疗原发性肝癌的研究进展[J]. 临床肿瘤学杂志,2017,22(10):950-53.
[91] 路大鹏,王玉强,赵卫林,等. 康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究[J]. 世界临床医学,2017,11(5):70,72.
[92] 高继良. 肝复乐方剂治疗晚期原发性肝癌的前瞻性、随机对照临床研究[J]. 中国中药杂志,2014,39(12):2367-2369.
[93] 范隼,李庆源,周志涛,等. TACE联合金龙胶囊治疗原发性肝癌的效果研究[J]. 中国实用医药,2019,14(21):42-44.
[94] 蔡文辉,尹春丽,范庆秋. 艾迪联合肝动脉化疗栓塞术治疗中晚期原发性肝癌的临床观察[J]. 中国医师杂志,2018,20(11):1723-1725.
[95] 杨新华. TACE联合鸦胆子油乳液静脉滴注对肝癌患者的临床疗效及VEGF水平的影响[J]. 海峡药学,2017,29(09):176-177.
[96] 彭文达. 复方斑蝥胶囊联合化疗治疗中晚期原发性肝癌的临床疗效观察[J]. 肿瘤药学,2011,1(6):518-519+543.
[97] SIMON TG,DUBERG AS,ALEMAN S, et al.Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality[J].N Engl J Med, 2020, 382(11):1018-1028.
[98] LEE TY,HSU YC,TSENG HC, et al.Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B[J].JAMA Intern Med, 2019, 179(5):633-640.